Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
Presentations to Explore Paxalisib’s Differentiated Tumor and Immune Reprogramming Activity SYDNEY, Nov.…
InventisBio Announces Topline Results of a Phase III Study of Nomelcitinib (TYK2 Inhibitor), Demonstrating Promising Efficacy and Safety in Patients with Moderate to Severe Plaque Psoriasis.